Overview
NeoGenomics Q3 revenue rises 12% to $188 mln, beating analyst expectations
Net loss for Q3 increases 53% to $27 mln
Adjusted EBITDA for Q3 declines 9% to $12 mln
Outlook
NeoGenomics reaffirms full-year 2025 guidance for revenue, net loss, and adjusted EBITDA
Company expects clinical volume growth to drive Q4 performance and 2026 momentum
Result Drivers
CLINICAL REVENUE GROWTH - Clinical revenue grew 18%, driven by increased test volumes and strategic reimbursement initiatives
NGS REVENUE INCREASE - NGS revenue rose 24% YoY, now accounting for nearly one-third of clinical revenue
OPERATING EXPENSES - Operating expenses rose 12% due to impairment charges and higher compensation costs
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $188 mln | $183.76 mln (14 Analysts) |
Q3 Adjusted Net Income | $3.60 mln | ||
Q3 Net Income | -$27 mln | ||
Q3 Adjusted EBITDA | $12.20 mln | ||
Q3 Gross Profit | $80 mln | ||
Q3 Operating Expenses | $107 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Neogenomics Inc is $11.00, about 7.6% above its October 27 closing price of $10.16
The stock recently traded at 64 times the next 12-month earnings vs. a P/E of 32 three months ago
Press Release: ID:nBwnHXK2a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)